Mr. Speaker, imagine a young mother being diagnosed with a type of cancer that usually affects older women.
Imagine that there is no reliable early detection screening and that the average survival time is less than five years in 75% of cases.
Imagine that this same woman is resistant to the most effective chemotherapy and that her survival depends on experimental research protocols.
Imagine that one of the drugs is not covered by her insurance company and costs her $4,000 every three weeks. Imagine the pressure on her family's budget.
Imagine that the benefits from treatment will not be permanent and that she will soon have to travel if she wants to live longer.
That is the true story of a young mother in Louis-Hébert with ovarian cancer. What she wants is quite simple: to watch her daughters grow up for as long as she can. We can help her if we improve our research capacity and allow physical and financial access to experimental treatments.